He was also scared because the experiment showed, in a concrete way, that humanity was at the dawn of a new era, one in which our thoughts could theoretically be snatched from our heads. What was going to happen, Dr. Gallant wondered, when you could read thoughts the thinker might not even be consciously aware of, when you could see people’s memories?
Brains are talking to computers, and computers to brains. Are our daydreams safe?
Credit… By Derrick Schultz
Women with Alzheimer’s disease tend to live longer than men with the disease — and a new study suggests that a gene on the X chromosome may help explain why.
Each person typically has one pair of sex chromosomes in each cell of their body. People assigned female at birth typically have two X chromosomes, while people assigned male at birth typically have one X chromosome and one Y chromosome.
Researchers say a gene called KDM6A may explain why women with Alzheimer’s disease tend to live longer than men with the same condition.
MINNEAPOLIS — A new study is sounding the alarm for patients taking dozens of common prescription and over-the-counter drugs. Researchers find that taking a particular class of drug, anticholinergics, increases the risk of developing mild thinking and memory problems.
The study shows there are about 100 of these types of drugs in widespread use. These medications treat everything from colds to high blood pressure to depression.
The research, published in the journal Neurology, finds that people with genetic risk factors for Alzheimer’s disease are particularly susceptible to these issues. Overall, scientists reveal patients with no cognitive issues are 47 percent more likely to develop a mental impairment if they’re taking at least one anticholinergic drug.
With a pig-filled demonstration, Neuralink revealed its latest advancements in brain implants this week. But what do scientists think of Elon Musk’s company’s grand claims?
Sleep has critical roles in health and regeneration, and one of those is clearing the brain of metabolic waste, according to researchers from the US and Denmark.
Now, as reported in the journal Nature Communications, they’ve discovered in mice that the time of day matters, suggesting the process is controlled by circadian rhythms.
“Our group has shown that just being awake or asleep drastically changes how well the brain can clear waste,” says lead author Lauren Hablitz from the University of Rochester Medical Centre.
The researchers, Prof. Itamar Kahn of the Technion’s Rappaport Faculty of Medicine in Israel and Prof. Nancy Ratner of Cincinnati Children’s Hospital Medical Center (CCHMC), claimed that such a breakthrough demonstrates a potential new treatment for cognitive damages in the brain white matter, the areas of the central nervous system.
“The participants treated with AMX0035 demonstrated a significant slowing of ALS disease progression as measured by the ALSFRS-R. This is a milestone in our fight against ALS,” said Sabrina Paganoni, MD, Ph.D., principal investigator of the CENTAUR study.
An experimental medication slows the progression of the neurodegenerative disease called Amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, according to recently released results from a clinical trial run by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) and Amylyx Pharmaceuticals, Inc., the company that manufactures the medication. The findings, reported in the New England Journal of Medicine, offer hope that a treatment may one day be available for patients with ALS, a fatal condition with no cure that attacks the nerve cells in the brain and the spinal cord to progressively hinder individuals’ ability to move, speak, eat, and even breathe.
Called AMX0035, the oral medication is a combination of two drugs, sodium phenylbutyrate and taurursodiol, that each target a different cell component important for protecting against nerve cell death.
In the CENTAUR trial, 137 participants with ALS were randomized in a two-toone ratio to receive AMX0035 or placebo. Over six months, participants who were treated with AMX0035 had better functional outcomes than those treated with placebo as measured by the ALS Functional Rating Scale (ALSFRS-R), a questionnaire that evaluates several activities of daily living such as a patient’s ability to walk, hold a pen or swallow food.